Bupropion and dextromethorphan for treating nicotine addiction
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1. A method of treating nicotine addiction comprising administering a combination of a bupropion and a dextromethorphan to a person suffering from nicotine addiction.
2. The method of claim 1 , wherein the combination of the bupropion and the dextromethorphan is administered to the person at least daily for 21 consecutive days.
3. The method of claim 1 , wherein the combination of the bupropion and the dextromethorphan is administered to the person at least daily for 42 consecutive days.
4. The method of claim 1 , wherein about 50 mg to about 150 mg of the bupropion is administered to the person daily.
5. The method of claim 1 , wherein about 150 mg to about 250 mg of the bupropion is administered daily to the person in two divided doses.
6. The method of claim 1 , wherein about 100 mg to about 200 mg of the bupropion is administered to the person daily.
7. The method of claim 1 , wherein about 250 mg to about 350 mg of the bupropion is administered to the person daily in two divided doses.
8. The method of claim 1 , wherein about 10 mg to about 20 mg of the dextromethorphan is administered to the person daily.
9. The method of claim 1 , wherein about 20 mg to about 30 mg of the dextromethorphan is administered to the person daily.
10. The method of claim 1 , wherein about 30 mg to about 40 mg of the dextromethorphan is administered to the person daily.
11. The method of claim 1 , wherein about 40 mg to about 50 mg of the dextromethorphan is administered to the person daily.
12. The method of claim 1 , wherein about 10 mg to about 20 mg of the dextromethorphan is administered to the person twice daily.
13. The method of claim 1 , wherein, to the average person addicted to nicotine, the method is more effective than administering bupropion alone.
14. The method of claim 1 , wherein, to the average person addicted to nicotine, the method is more effective than administering dextromethorphan alone.
15. The method of claim 1 , wherein about 150 mg of the bupropion is administered to the person once daily for three days, followed by administering 150 mg of the bupropion twice daily to the person for at least 39 days.
16. The method of claim 15 , wherein, to the average person addicted to nicotine, the method is more effective, as measured on day 42 of treatment, than a control method, wherein the control method consists of administering 150 mg of bupropion to the person once daily for three days, followed by administering 150 mg of bupropion twice daily to the person for 39 days.
17. The method of claim 1 , wherein about 105 mg of the bupropion is administered to the person once daily for three days, followed by administering 105 mg of the bupropion twice daily to the person for at least 39 days.
18. The method of claim 17 , wherein, to the average person addicted to nicotine, the method is more effective, as measured on day 42 of treatment, than a control method, wherein the control method consists of administering 150 mg of bupropion to the person once daily for three days, followed by administering 150 mg of bupropion twice daily to the person for 39 days.
19. The method of claim 17 , wherein, to the average person addicted to nicotine, the method is more effective, as measured on day 42 of treatment, than a control method, wherein the control method consists of administering 105 mg of bupropion to the person once daily for three days, followed by administering 105 mg of bupropion twice daily to the person for 39 days.
20. The method of claim 1 , wherein about 45 mg of the dextromethorphan is administered to the person once daily for three days, followed by administering 45 mg of the dextromethorphan twice daily to the person for at least 39 days.
21. The method of claim 1 , wherein the bupropion has an enantiomeric excess of the R-enantiomer that is at least 90%.
22. The method of claim 1 , wherein the bupropion has an enantiomeric excess of the S-enantiomer that is at least 90%.
23. The method of claim 1 , wherein the bupropion is deuterium enriched.
24. The method of claim 1 , wherein the dextromethorphan is deuterium enriched.